Therapies in non‐alcoholic steatohepatitis (NASH)
Open Access
- 3 January 2017
- journal article
- review article
- Published by Wiley in Liver International
- Vol. 37 (S1), 97-103
- https://doi.org/10.1111/liv.13302
Abstract
The hallmark of non‐alcoholic fatty liver disease (NAFLD) is excessive fatty accumulation in the hepatocytes, which may be an isolated event (non‐alcoholic fatty liver, NAFL) or accompanied by evidence of inflammation and cell injury with or without fibrosis (non‐alcoholic steatohepatitis, NASH). NASH, the more aggressive form of NAFLD, may progress to cirrhosis and hepatocellular carcinoma. Since NASH is estimated to overtake hepatitis C virus infection as the leading cause of liver transplantation in the US in the coming decade, and there are no current FDA‐approved therapies for this disease, the need to find appropriate therapeutic targets is now more urgent than ever before. Diet and other lifestyle modifications have always been difficult to maintain and this approach alone has not slowed the rising tide of the disease. While the results of traditional therapies such as vitamin E and pioglitazone have been significant for steatosis and inflammation, they have had no effect on fibrosis, which is the strongest indicator of mortality in this condition. However, the understanding of the pathogenesis and progression of NASH has evolved and several promising novel therapies to target and possibly reverse fibrosis are being evaluated, making the future outlook of NASH therapy more optimistic.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK 7150-40, RO1 DK 081450)
This publication has 91 references indexed in Scilit:
- A Two-Year Randomized Trial of Obesity Treatment in Primary Care PracticeThe New England Journal of Medicine, 2011
- Effect of Vitamin E or Metformin for Treatment of Nonalcoholic Fatty Liver Disease in Children and AdolescentsPublished by American Medical Association (AMA) ,2011
- FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen SynthesisScience, 2011
- A position statement on NAFLD/NASH based on the EASL 2009 special conferenceJournal of Hepatology, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisThe New England Journal of Medicine, 2010
- Apoptosis and Cytokines in Non-Alcoholic SteatohepatitisClinics in Liver Disease, 2009
- Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitisHepatology, 2009
- Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2008
- Mortality in Randomized Trials of Antioxidant Supplements for Primary and Secondary PreventionJama-Journal Of The American Medical Association, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology, 2005